What's breaking now, across thousands of outlets.
Israeli pharmaceutical giant Teva receives FDA approval for WELTRUZA, a new long-acting injection for schizophrenia that eliminates the need for daily medication.
We haven't written up this one. Arutz Sheva - Israel National News has the full story — the link below goes straight to it.
A Healthcare Dive analysis of highly anticipated stars data for next year shows a potpourri of winners and losers, though — as expected — the quality scores slipped overall.
This article is from Food for Feed, a series investigating the global fishmeal industry. It is produced by the Outlaw Ocean Project, a news organization based in Washington, D.C., and excerpted by…
KUALA LUMPUR: The Health Ministry's RM47.7 billion allocation under the 2027 Budget is insufficient to meet growing healthcare demands, with development expenditure remaining virtually unchanged, says…
The Ghana Atomic Energy Commission (GAEC) has warned Ghanaians about the risk of lung cancer from exposure to radon gas, urging households to improve ventilation by keeping windows open to prevent the…
Teva has received FDA approval for once monthly injectable schizophrenia drug Weltruza. The announcement sent Teva shares gaining in premarket.
(MedPage Today) -- Three women experienced neurological symptoms after injections of botulinum toxin at a medical spa in Colorado, which turned out to be an unapproved product, public health officials…
